Eisai Inc., of Woodcliff Lake, N.J., said it entered an agreement with Concordia Pharmaceuticals Inc., of Barbados, a subsidiary of Concordia Healthcare Corp., to purchase Eisai's U.S. and Puerto Rican commercialization and distribution rights to epilepsy drug Zonegran (zonisamide).